GSK Invests $800 Million in Pennsylvania Site Expansion to Boost Vaccine and Medicine Production

Investment Amount:
GSK is investing up to $800 million to expand its manufacturing site in Marietta, Pennsylvania.

Expansion Details:
The expansion will double the size and capacity of the site, enabling the production of sterile liquid vaccines and medicines, as well as an R&D pilot plant for clinical trials.

Job Creation:
The project will create more than 200 new jobs and retain at least 4,622 jobs statewide.

Sustainability:
The new facilities will incorporate sustainable features such as solar panels, electric heat generation, and water and energy reclamation to reduce carbon emissions.

Timeline:
Construction is expected to start by the end of 2024, with the drug substance facility operational by the end of 2027 and the drug product facility by the end of 2028.

Government Support:
The Commonwealth of Pennsylvania is supporting the expansion with a $21 million investment, including grants and tax credits.

Impact:
The expansion will establish Marietta as an innovation and manufacturing hub for next-generation medicines and vaccines.